Markets · News reference
Filed: 2026-09-08 AccNo: 0001705696-26-000092 Size: 208 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
Keep reading
Barnes & Noble Education reported a Q1 loss of $0.37 per share, beating expectations of a $0.50 loss, but missed revenue estimates with $290.6 million versus the consensus estimate. Despite the revenue miss, the stock has gained 38.4% year-to-date and holds a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.
Braze (BRZE) reported Q2 2026 earnings of $0.19 per share, beating consensus estimates of $0.16, with revenues of $227.23 million exceeding expectations by 3.19%. However, the stock has underperformed the S&P 500 by 19.6% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Meanwhile, Penguin Solutions (PENG) is expected to report quarterly earnings of $0.75 per share, representing 74.4% year-over-year growth, with revenues projected at $512.5 million, up 51.7% from the prior year.
Qualcomm shares rose 8.7% following a partnership announcement with Amazon to develop custom AI chips for AWS data centers. Amazon also obtained a warrant to purchase up to 25 million Qualcomm shares at $161.26 per share, contingent on up to $60 billion in chip orders. The deal positions Qualcomm to capitalize on the AI data center buildout as smartphone market growth slows.
Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.
Reshoring in U.S. manufacturing often involves replacing imported components with domestic capacity rather than relocating entire factories. While reshoring offers benefits like faster delivery and supply chain resilience, U.S. manufacturers face significant price competition, with 94% of contract manufacturers citing price as the main reason for losing orders to imports. MP Materials exemplifies reshoring opportunities through its rare-earth magnet production expansion in Texas, supported by Pentagon guarantees. However, manufacturing construction spending has declined 32% since September 2024, suggesting investors should verify whether reshoring interest translates into actual orders and earnings growth.
CoreWeave shares gained 12% today despite no company-specific news, benefiting from a broader rally in the AI infrastructure sector. The gains were driven by Nebius's partnership announcement with Palantir, Department of Commerce investments in quantum computing companies, and Intel's processor price increase announcement. CoreWeave remains a volatile, high-risk stock with rapid revenue growth but massive losses due to heavy capital expenditures and debt servicing.